The Center for Biosimilars® recaps the top stories for the week of September 30, 2019.
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 30, 2019.
Number 5: A new report from the House Ways and Means Committee finds that Americans pay nearly 4 times more for drugs than do patients in other countries.
Number 4: During the week’s European Society for Medical Oncology Congress 2019, a research team presented findings from a phase 3 trial of Samsung Bioepis' proposed bevacizumab biosimilar.
Number 3: New research suggests that state-level drug price transparency laws are largely ineffective at revealing true transaction prices.
Number 2: A newly introduced item of legislation proposes to eliminate co-payments for patients when they receive biosimilars in Medicare Part B.
Number 1: Pfizer says that it will launch its bevacizumab biosimilar, Zirabev, in the United States on December 31.
Finally, last week, our e-newsletter asked whether you think that biosimilars of rituximab will make treatment more accessible for patients with neurological diseases like multiple sclerosis.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.